Background
Methods
Objectives
Description of the Region
Patient selection
Study design
Exhaustiveness control
Main outcome measure
Grading system
Subgroup analysis
Statistical analysis
Results
Characteristics of selected patients and tumors
Characteristics of included patients and tumors
Number | % | |
---|---|---|
Included patients | 366 | 100% |
Types of sarcoma
| ||
Soft tissue | 215 | 59 |
Visceral tissue | 130 | 35 |
Bone tissue | 21 | 6 |
Tumor site
| ||
Abdomen | 101 | 27.6 |
Lower limb | 76 | 20.8 |
Thorax | 54 | 14.8 |
Pelvis | 45 | 12.3 |
Upper limb | 34 | 9.3 |
Head and Neck | 29 | 7.9 |
Retroperitoneum | 21 | 5.7 |
Multiple localizations | 5 | 1.4 |
Axial skeleton | 1 | 0.3 |
Histological subtype
| ||
GIST | 65 | 17.8 |
Liposarcoma | 56 | 15.3 |
NOS Sarcoma * | 52 | 14.2 |
Other ** | 38 | 10.3 |
Leiomyosarcoma | 26 | 7.1 |
Dermatofibrosarcoma protuberans | 20 | 5.5 |
Kaposi sarcoma | 18 | 4.9 |
Uterine leiomyosarcoma | 12 | 3.3 |
Myxofibrosarcoma | 12 | 3.3 |
Osteosarcoma | 11 | 3.0 |
Angiosarcoma | 10 | 2.7 |
Chondrosarcoma | 9 | 2.5 |
PNET/Ewing sarcoma | 8 | 2,2 |
Rhabdomyosarcoma | 8 | 2.2 |
Synovial sarcoma | 7 | 1,9 |
Unclassified malignant connective tumors | 14 | 3.8 |
Grade
| ||
I | 85 | 23.2 |
II | 77 | 21.0 |
III | 97 | 26.5 |
Not applicable*** | 103 | 28.1 |
Unknown | 4 | 1.1 |
Concordance analysis
Concordance
| Zero | Partial | Full |
p
|
---|---|---|---|---|
Included tumors | 70 (100%) | 97 (100%) | 199 (100%) | |
Type of laboratory
| ||||
Public
| 17 (16.8%) | 28 (27.7%) | 56 (55.4%) |
0.78
|
Private
| 53 (20%) | 69 (26.%) | 143 (54%) | |
Concordance
|
Zero
|
Partial
|
Full
|
p
|
Included tumors | 70 | 97 | 97 | |
Type of tumor sample
| ||||
Biopsy
| 16 (17.2%) | 23 (24.7%) | 54 (58.1%) |
0.70
|
Surgical specimen
| 54 (19.8%) | 74 (27.1%) | 145 (53.1%) | |
Concordance
|
Zero
|
Partial
|
Full
|
p
|
Included tumors | 44 | 81 | 134 | |
Grade
| ||||
I
| 9 (10.6%) | 21 (24.7%) | 55 (64.7%) |
0.01
|
II-III
| 35 (20.1%) | 60 (34.5%) | 79 (45.4%) | |
Concordance
|
Zero
|
Partial
|
Full
|
p
|
Included tumors | 67 | 97 | 199 | |
Molecular biology study
| ||||
No
| 45 (20%) | 61 (26.%) | 127 (54%) |
0.84
|
Yes
| 23(17.6%) | 36 (27.5%) | 72 (55.0%) |
Reasons for non-concordance | Frequency | % |
---|---|---|
Grade | 68 | 18.5 |
Histological type | 39 | 10.7 |
Grade and Histological type | 30 | 8.2 |
Subtype | 17 | 4.6 |
Grade and subtype | 13 | 3.6 |
SUB-TOTAL
|
167
|
45.6
|
Patient with total agreement
|
199
|
54.4
|
TOTAL
| 366 |
100
|
Expert diagnosis | Initial diagnosis | Frequency (n = 70) |
---|---|---|
NOS Sarcoma | MPNST | 1 |
NOS Sarcoma | Angiosarcoma | 1 |
NOS Sarcoma | Unclassified malignant tumor | 6 |
NOS Sarcoma | Leiomyosarcoma | 1 |
NOS Sarcoma | GIST | 1 |
NOS Sarcoma | Chondrosarcoma | 1 |
NOS Sarcoma | Embryonic Rhabdomyosarcoma | 1 |
NOS Sarcoma | Benign Tumor | 1 |
NOS Sarcoma | Liposarcoma | 1 |
NOS Sarcoma | Leiomyosarcoma | 2 |
Leiomyosarcoma | Benign Tumor | 2 |
Leiomyosarcoma | NOS Sarcoma | 1 |
Osteosarcoma | NOS Sarcoma | 1 |
Osteosarcoma | Unclassified malignant tumor | 1 |
Osteosarcoma | Melanoma | 1 |
Lipoma-like Liposarcoma | Benign Tumor | 1 |
Lipoma-like Liposarcoma | Fibrosarcoma | 1 |
Lipoma-like Liposarcoma | Unclassified malignant tumor | 1 |
Liposarcoma | Benign Tumor | 1 |
Liposarcoma | NOS Sarcoma | 2 |
Dedif. Liposarcoma | Leiomyosarcoma | 2 |
Dedif. Liposarcoma | Unclassified malignant tumor | 1 |
Dedif. Liposarcoma | NOS Sarcoma | 1 |
Myxofibrosarcoma | Liposarcoma | 1 |
Myxofibrosarcoma | NOS Sarcoma | 3 |
Myxofibrosarcoma | Sarcomatoid Carcinoma | 1 |
Myxofibrosarcoma | Chondrosarcoma | 1 |
Sarcomatoid Carcinoma | Leiomyosarcoma | 1 |
Sarcomatoid Carcinoma | NOS Sarcoma | 3 |
Angiosarcoma | Unclassified malignant tumor | 1 |
Angiosarcoma | Synovial sarcoma | 1 |
Benign Tumor | Inflammatory MyxofibroSarcoma | 1 |
Benign Tumor | Leiomyosarcoma | 1 |
Benign Tumor | Well-differenciated lipoma-like Liposarcoma | 1 |
Epithelioid Sarcoma | Unclassified malignant tumor | 1 |
Epithelioid Sarcoma | Synovial sarcoma | 1 |
PNET/Ewing sarcoma | Carcinoma | 2 |
PNET/Ewing sarcoma | Unclassified malignant tumor | 3 |
Rhabdomyosarcoma | Leiomyosarcoma | 1 |
GIST | NOS Sarcoma | 1 |
Carcinoma | Phyllodes Tumor | 1 |
Carcinoma | NOS Sarcoma | 1 |
Solitary fibrosis/malignant Tumor | GIST | 1 |
Uterine Leiomyosarcoma | Benign Tumor | 1 |
PEComa | Unclassified malignant tumor | 1 |
Fibrosarcoma | Unclassified malignant tumor | 1 |
Endometrial Stromal Sarcoma | Leiomyosarcoma | 1 |
Epithelioid Hemangioendothelioma | Carcinoma | 1 |
Inflammatory Myxofibrosarcoma | Epithelioid Sarcoma | 1 |
Unclassified malignant tumor | Carcinoma | 1 |
Low grade fibromyxoid Sarcoma | Benign Tumor | 1 |
Kaposi sarcoma | NOS Sarcoma | 1 |
Synovial sarcoma | Benign Tumor | 1 |
Dermatofibrosarcoma protuberans | Benign Tumor | 1 |
Requested SO group versus control group
Patient characteristics. | |||
---|---|---|---|
requested SO group | Control group |
p
| |
Included patients | 188 (100%) | 178 (100%) | |
Sex
| |||
Males
| 102 (54.3%) | 82 (46.1%) |
0.117
|
Females
| 86 (45.7%) | 96 (53.9%) | |
Age (years)
| |||
Mean
| 57.9 | 59.6 | |
Median
| 62 | 61 |
0.359
|
Range
| [15-86] | [18-92] | |
Types of tumor
| |||
Soft tissue
| 117 (62.2%) | 98 (55.1%) | |
Bone tissue
| 13 (6.9%) | 8 (4.5%) |
0.128
|
Visceral tissue
| 58 (30.9%) | 72 (40.4%) | |
Localization
| |||
Upper limb
| 15 (8.%) | 19 (10.7%) | |
Lower limb
| 45 (23.9%) | 31 (17.4%) | |
Abdomen
| 44 (23.4%) | 57 (32%) | |
Thorax
| 31 (16.5%) | 23 (12.9%) |
0.313
|
Head and Neck
| 16 (8.5%) | 13 (7.3%) | |
Pelvis
| 25 (13.3%) | 20 (11.2%) | |
Retroperitoneum
| 10 (5.3%) | 11 (6.2%) | |
Axial skeleton
| 1 (0.5%) | 0 (0%) | |
Multiple localizations
| 1 (0.5%) | 4 (2.2%) | |
Grade
| |||
Grade I
| 47 (25%) | 38 (21.3%) | |
Grade II
| 36 (19.1%) | 41 (23%) | |
Grade III
| 50 (26.6%) | 47 (26.4%) |
0.716
|
Non applicable
| 52 (27.2%) | 51 (28.7%) | |
Unknown
| 3 (1.6%) | 1 (0.6%) | |
Histological subtypes
| |||
Liposarcoma
| 37 (19.7%) | 19 (10.7%) | |
NOS Sarcoma
| 32 (17.0%) | 20 (11.2%) | |
GIST
| 23 (12.2%) | 42 (23.6%) | |
Myxofibrosarcoma
| 9 (4.8%) | 3 (1.7%) | |
Leiomyosarcoma
| 7 (3.7%) | 19 (10.7%) | |
PNET/Ewing
| 6 (3.2%) | 2 (1.1%) | |
Rhabdomyosarcoma
| 6 (3.2%) | 2 (1.1%) |
< 0.001.
|
Chondrosarcoma
| 6 (3.2%) | 3 (1.7%) | |
Dermatofibrosarcoma
| 4 (2.1%) | 16 (9.0%) | |
protuberans
| |||
Uterine Leiomyosarcoma
| 5 (2.7%) | 7 (3.9%) | |
Osteosarcoma
| 5 (2.7%) | 6 (3.4%) | |
Kaposi Sarcoma
| 5 (2.7%) | 13 (7.3%) | |
Synovialosarcoma
| 5 (2.7%) | 2 (1.1%) | |
Angiosarcoma
| 3 (1.6%) | 7 (3.9%) | |
Unclassified malignant tumor
| 7 (3.7%) | 7 (3.9%) | |
Other
| 28 (14.9%) | 10 (5.6%) |
Concordance results in the two subgroups of patients
Requested SO group | Control group |
p
| |
---|---|---|---|
Included patients | 188 (100%) | 178 (100%) | |
Concordance
| |||
Zero
| 53 (28.2%) | 17 (9.6%) | |
Partial
| 53 (28.2%) | 44 (24.7%) |
< 0.001.
|
Full
| 82 (43.6%) | 117 (65.7%) | |
Included patients | 106 (100%) | 61 (100%) | |
Type of discordance
| |||
Subtype alone
| 10 (9.4%) | 7 (11.5%) | |
Grade alone
| 31 (29.2%) | 37 (60.7%) | |
Histological type alone
| 27 (25.5%) | 12 (19.7%) |
< 0.001
|
Grade + Subtype
| 13 (12.3%) | 0 (0%) | |
Grade + Histological type
| 25 (23.6%) | 5 (8.2%) |